ESR1 and breast cancer: In contrast, in patients with primary BC and not receiving adjuvant systemic hormone treatments, we found that fusion between ESR1 and CCDC170 in general, and between exon 2 of ESR1 and exon 8 of CCDC170 in particular, predicted in uni- and multivariable analyses shorter disease free survival as well as shorter overall survival.